Advertisement Pharmaceutical Business review - Page 112 of 5267 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 31, 2026

uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies

uBriGene Biosciences has signed a strategic partnership with Cellinfinity BIO to advance the clinical development of in vivo chimeric antigen receptor T-cell (CAR-T) therapy programmes for haematologic and solid tumours.

CIB-301 targets solid tumours using a fully human CAR scFv. Credit: Vshivkova / Shutterstock.com.